What Is the Strongest NSAID? Ranked by Potency

There is no single “strongest” NSAID because the answer changes depending on what you measure. For raw pain relief in a single dose, etoricoxib 120 mg tops most rankings, needing fewer than two patients treated for one to achieve meaningful relief. For sheer analgesic punch in a hospital setting, ketorolac has gone head-to-head with morphine and held its own. For long-term anti-inflammatory control in arthritis, etoricoxib and diclofenac consistently outperform other options. But potency and safety pull in opposite directions with these drugs, and the NSAID that hits hardest often carries the steepest risks.

How Pain Relief Potency Is Actually Measured

Researchers rank single-dose pain relief using a metric called the “number needed to treat,” or NNT. It answers a simple question: how many people need to take this drug for one person to get at least 50 percent of the maximum possible relief over four to six hours, compared with a sugar pill? A lower NNT means fewer people need to take the drug before one benefits, so lower is better. A large Cochrane overview pooled dozens of reviews of acute postoperative pain trials to produce a head-to-head comparison across drugs and doses. The standout performers, ranked from most to least potent for single-dose pain relief, looked like this:

Etoricoxib 120 mg: NNT of 1.9, meaning roughly one in every two people got strong relief
Ibuprofen 400 mg: NNT of 2.5
Celecoxib 400 mg: NNT of 2.5
Diclofenac 50 mg: NNT of 2.7
Naproxen 500 mg: NNT of 2.7

The gap between etoricoxib and the rest is real but not enormous. Over 70 percent of people taking etoricoxib achieved meaningful relief, while roughly half to two-thirds did so with ibuprofen, celecoxib, diclofenac, or naproxen at their standard doses. Time to re-dosing also varied widely, from about two hours for placebo to more than 20 hours with some of the stronger options in the same pain model.¹

Ketorolac and the Morphine Comparison

Ketorolac occupies a unique spot in the NSAID world. It is primarily given by injection or as a short-course oral medication, and it is the NSAID most often compared directly to opioids. In a postoperative trial, ketorolac 30 mg matched or slightly outperformed morphine 4 mg intravenously on most pain measures, and both were clearly superior to morphine 2 mg.² A separate trial after major surgery found ketorolac 30 mg generally more effective than intramuscular morphine 10 mg, with ketorolac 10 mg alone already outperforming morphine 10 mg on hourly pain scores.³

That performance comes at a cost. A recent meta-analysis found ketorolac carried the highest risk of gastrointestinal bleeding of any NSAID studied, with an odds ratio above 20 compared to non-use. That is roughly nine times the bleeding risk of ibuprofen and nearly 18 times the risk of celecoxib.⁴ This is why ketorolac is limited to short courses, usually five days or fewer, and is not prescribed for routine aches and pains.

Anti-Inflammatory Potency for Arthritis

Pain relief in a dental surgery trial and long-term inflammation control in osteoarthritis are different things. When researchers look at which NSAIDs keep arthritis patients on their medication longest with the fewest dropouts for inadequate relief, etoricoxib again rises to the top. A Bayesian network meta-analysis found that etoricoxib at 30 to 60 mg daily had the highest probability of being the best-performing treatment for osteoarthritis, ahead of celecoxib 200 to 400 mg and naproxen 1000 mg, though the differences between the three did not reach statistical significance.⁵

A separate mixed-treatment comparison across randomized trials confirmed that result: etoricoxib at just 30 mg had a greater than 95 percent probability of producing the largest improvement in pain and physical function compared with celecoxib, ibuprofen, and diclofenac at their standard doses.⁶ In two identically designed trials, etoricoxib 30 mg was non-inferior to celecoxib 200 mg, and both were clearly superior to placebo for pain, stiffness, and function.⁷ For acute gout flares, where strong anti-inflammatory action matters most, etoricoxib and indomethacin showed comparable efficacy across patient subgroups.⁸

Worth noting: etoricoxib is widely available in Europe, Latin America, and parts of Asia but has never been approved by the FDA for sale in the United States. American readers searching for “the strongest NSAID” will not find it at their pharmacy. Indomethacin and diclofenac are the closest alternatives on the U.S. market for high-potency anti-inflammatory needs.

The Ceiling Effect

Potency rankings can mislead you if you assume that doubling the dose doubles the relief. NSAIDs have a ceiling effect for pain: beyond a certain dose, taking more does not reduce pain further, it only increases side effects. For ibuprofen, the ceiling appears to sit at around 400 mg per dose. A randomized trial comparing 400, 600, and 800 mg of ibuprofen found no additional analgesic benefit above 400 mg in moderate postoperative pain.⁹ A meta-analysis of NSAIDs for cancer pain found the same pattern across multiple drugs: going above the recommended single dose did not produce better pain scores.¹⁰

The anti-inflammatory ceiling is higher than the analgesic ceiling, which is why doctors sometimes prescribe 800 mg ibuprofen three times daily for inflammation even though 400 mg handles pain just as well. But the side-effect curve keeps climbing with the dose, so there is no free lunch.

COX Selectivity and Why It Matters

NSAIDs work by blocking cyclooxygenase enzymes. There are two main forms: COX-1, which helps protect the stomach lining and supports kidney blood flow, and COX-2, which drives inflammation and pain. How selectively an NSAID hits one over the other shapes both its benefits and its harms. An analysis of more than 40 NSAIDs found that the more strongly a drug favors COX-1 inhibition, the greater its risk of serious gastrointestinal complications.¹¹

The selectivity spectrum is broad. In a widely cited blood assay study, flurbiprofen and ketoprofen were strongly COX-1 selective, ibuprofen and naproxen were roughly nonselective, and diclofenac and mefenamic acid leaned toward COX-2.¹² In a separate cell-based assay, indomethacin was the most potent COX-1 inhibitor tested, with celecoxib and meloxicam sitting far on the COX-2-selective end.¹³

One complication: lab results and real-world behavior do not always line up. Diclofenac looks like a selective COX-2 inhibitor in a test tube, but after someone swallows a pill, it also inhibits a substantial amount of COX-1. Ibuprofen looks like a COX-1 preferrer in vitro, yet it inhibits COX-2 by about 80 percent after oral dosing. The researchers who documented this mismatch concluded that predicting real clinical selectivity from lab assays has “limited clinical relevance.”¹⁴

Gastrointestinal Bleeding Risk by Drug

The risk of GI bleeding is not evenly spread across NSAIDs, and the differences are dramatic. The same meta-analysis that flagged ketorolac’s outsized bleeding risk found the full spectrum looks roughly like this: celecoxib carried the lowest risk, with an odds ratio of about 1.2 compared with non-use, meaning its risk was barely distinguishable from taking nothing at all. Among nonselective NSAIDs, ibuprofen had the lowest significant risk at about 2.3 times baseline. Piroxicam and meloxicam showed notably elevated risks, and ketorolac was the clear outlier at roughly 21 times baseline risk.⁴ These numbers matter a great deal for people who need daily NSAID therapy: a drug that is slightly less potent for pain but carries a fraction of the GI risk may be the smarter clinical choice.

Cardiovascular Risk Runs in the Opposite Direction

Choosing an NSAID based on stomach safety alone would be straightforward if not for the heart. A large network meta-analysis comparing cardiovascular outcomes found that the risks are distributed differently than GI risks. Rofecoxib (the withdrawn COX-2 inhibitor Vioxx) had the highest heart attack risk, about double that of placebo. For stroke, ibuprofen carried the highest risk, followed by diclofenac. And for cardiovascular death, etoricoxib and diclofenac stood out with the highest rates.¹⁵ Clinical trial databases across the class have documented variable rates of blood pressure destabilization, arrhythmias, heart failure, heart attacks, and strokes.¹⁶

This creates a genuine dilemma. The drugs that look safest for the gut (celecoxib, etoricoxib) are COX-2-selective agents whose class came under scrutiny after the rofecoxib scandal. The drugs with relatively lower cardiovascular signals (naproxen is often cited as the safest for the heart, though evidence is mixed) tend to be harder on the stomach. No NSAID is risk-free for either organ system, and the “strongest” drug is not automatically the best choice if a patient has risk factors for cardiovascular disease.

Kidney Risks Across the Class

NSAIDs reduce the production of prostaglandins that keep blood vessels in the kidneys dilated. Without those prostaglandins, the blood vessels constrict, and in vulnerable people this can starve kidney tissue of blood flow, causing acute kidney injury.¹⁷ The two COX enzymes appear to play opposing roles in the kidney: inhibiting COX-1 increases salt excretion and lowers blood pressure, while inhibiting COX-2 promotes sodium retention and raises it.¹⁸ This means COX-2-selective drugs are not necessarily gentler on the kidneys; they may actually worsen fluid retention and blood pressure more than nonselective alternatives.

People with existing kidney disease, heart failure, liver cirrhosis, or dehydration are at the highest risk. For them, the potency ranking of an NSAID matters much less than whether they should be taking one at all. Short courses at the lowest effective dose remain the standard advice, regardless of which drug is chosen.

How Formulation Changes What You Feel

Two pills containing the same drug at the same dose can feel very different depending on how the pill is designed. Ibuprofen arginate, a salt form of standard ibuprofen, reaches meaningful pain relief about twice as fast as conventional ibuprofen tablets. In a dental pain trial, the 400 mg arginate version hit meaningful relief in 24 minutes compared to 48 minutes for the regular tablet, driven by dramatically higher blood levels at 30 minutes.¹⁹ Pharmacokinetic modeling confirms that faster-dissolving formulations primarily affect how quickly the drug starts working, not the total amount of relief.²⁰

Topical NSAIDs are a different story. When diclofenac is applied as a gel or patch over a sore knee, it delivers far more drug to the muscle underneath than an oral dose does. One study found roughly 14 times more diclofenac in the muscle after topical application compared to oral dosing, while plasma levels stayed comparable or lower.²¹ Topical delivery sustains tissue drug levels for several hours, with a much lower ratio of blood-to-tissue drug concentration than oral delivery achieves.²² Because less drug reaches the bloodstream, topical diclofenac causes significantly fewer GI side effects than oral diclofenac, and less disruption to liver enzymes, hemoglobin, and kidney function markers. The main tradeoff is dry skin at the application site.²³

Some NSAIDs also appear to accumulate and persist in inflamed tissue while clearing quickly from the blood, heart, and kidneys. This property may partly explain why certain drugs deliver strong relief with relatively tolerable side-effect profiles.²⁴ The transdermal route takes this principle further: even though total blood levels are lower, the concentration at the site of pain can exceed what’s needed for effective COX-2 inhibition, while COX-1 inhibition in the gut stays minimal.²⁵

Why the Same Drug Works Differently in Different People

Anyone who has tried two or three NSAIDs knows that what works brilliantly for one person can feel like a placebo to someone else. Part of this is genetic. Most NSAIDs are processed in the liver by an enzyme called CYP2C9, and common genetic variants in the gene coding for that enzyme change how quickly or slowly a person clears the drug from their body. Slow metabolizers end up with higher drug exposure from the same dose, which can mean both stronger effects and a greater risk of side effects. The Clinical Pharmacogenetics Implementation Consortium has published guidelines for adjusting NSAID prescribing based on CYP2C9 status.²⁶

Age compounds this variability. Older adults tend to have reduced kidney function, lower liver metabolism, and more co-medications that interact with NSAIDs. They are also more prone to GI bleeds and cardiovascular events, making the risk-benefit equation tilt more steeply than it does for a 30-year-old with a sports injury.²⁷ For these patients, the “strongest” NSAID is rarely the right choice. A moderate-potency drug at the lowest effective dose, or a topical formulation, usually makes more sense.

Combining an NSAID with Acetaminophen

If a single NSAID has hit its ceiling, one way to squeeze out more relief is to add acetaminophen (paracetamol), which works through a different mechanism. A Cochrane review of this combination found that ibuprofen 400 mg plus acetaminophen 1000 mg produced meaningful pain relief in about 73 percent of people, compared with 52 percent for ibuprofen 400 mg alone. The number needed to treat for the combination versus ibuprofen alone was about 5.4, meaning roughly one in every five or six patients got additional benefit from adding acetaminophen. Adverse events were actually lower with the combination than with placebo, likely because fewer people needed rescue medication.²⁸

This combination is worth knowing about because it offers a practical way to boost pain control without escalating to a stronger NSAID or adding an opioid. For situations like dental extractions or minor surgical recovery, it can outperform either drug on its own.

Pain Relief Beyond COX Inhibition

The textbook story that NSAIDs reduce pain only by blocking prostaglandin production at the injury site is incomplete. Research has shown that NSAIDs also act within the central nervous system, particularly on the brain’s own pain-suppression pathways. One of the key targets is a descending system that sends signals from the brainstem down to the spinal cord to dampen incoming pain signals. This central action appears to involve endocannabinoid receptors, meaning NSAIDs partly piggyback on the same system that cannabinoids activate.²⁹ Other proposed central mechanisms include interference with G-protein signaling pathways unrelated to prostaglandins, involvement of the body’s own opioid peptides, blockade of serotonin release, and inhibition of excitatory amino acid signaling.³⁰

These additional mechanisms help explain why some NSAIDs seem to punch above their weight in pain models even when their COX inhibition profile looks unremarkable. They also help explain why switching between NSAIDs sometimes works: even though two drugs block the same enzyme, they may differ in how strongly they engage these central pathways. The science here is still being worked out, but it is a reminder that ranking NSAIDs purely by how hard they hit COX-2 misses part of the picture.